 Christopher Filley
Concepts (484)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| White Matter | 12 | 2023 | 115 | 6.470 |
Why?
| | Leukoencephalopathies | 11 | 2022 | 32 | 6.460 |
Why?
| | Brain | 50 | 2023 | 2481 | 3.290 |
Why?
| | Cognition Disorders | 26 | 2017 | 528 | 3.160 |
Why?
| | Cognition | 17 | 2022 | 1026 | 2.740 |
Why?
| | Dementia | 19 | 2020 | 207 | 2.730 |
Why?
| | Cognitive Dysfunction | 10 | 2021 | 301 | 2.300 |
Why?
| | Brain Diseases | 11 | 2020 | 141 | 2.170 |
Why?
| | Alzheimer Disease | 29 | 2023 | 512 | 2.100 |
Why?
| | Neuropsychological Tests | 39 | 2021 | 1027 | 2.050 |
Why?
| | Lupus Erythematosus, Systemic | 12 | 2018 | 228 | 1.990 |
Why?
| | Nerve Fibers, Myelinated | 6 | 2013 | 46 | 1.920 |
Why?
| | Chronic Traumatic Encephalopathy | 2 | 2023 | 18 | 1.570 |
Why?
| | Mental Disorders | 13 | 2021 | 935 | 1.540 |
Why?
| | Neurology | 3 | 2022 | 94 | 1.330 |
Why?
| | Memory Disorders | 7 | 2016 | 168 | 1.240 |
Why?
| | Leukoaraiosis | 2 | 2021 | 4 | 1.220 |
Why?
| | Brain Concussion | 4 | 2023 | 461 | 1.160 |
Why?
| | Toluene | 7 | 2022 | 20 | 1.130 |
Why?
| | Brain Injuries, Traumatic | 3 | 2021 | 310 | 1.110 |
Why?
| | Ataxia | 2 | 2016 | 38 | 1.080 |
Why?
| | Tremor | 2 | 2016 | 46 | 1.060 |
Why?
| | Frontal Lobe | 7 | 2019 | 147 | 1.050 |
Why?
| | Magnetic Resonance Imaging | 39 | 2022 | 3169 | 1.040 |
Why?
| | Brain Injuries | 11 | 2020 | 480 | 1.040 |
Why?
| | Fragile X Syndrome | 2 | 2016 | 80 | 1.020 |
Why?
| | Neural Pathways | 7 | 2019 | 277 | 0.980 |
Why?
| | Humans | 147 | 2023 | 118268 | 0.960 |
Why?
| | Fragile X Mental Retardation Protein | 4 | 2016 | 65 | 0.890 |
Why?
| | Football | 3 | 2015 | 86 | 0.890 |
Why?
| | Tauopathies | 1 | 2023 | 8 | 0.890 |
Why?
| | Temporal Lobe | 4 | 2019 | 90 | 0.880 |
Why?
| | Opiate Alkaloids | 1 | 2022 | 7 | 0.880 |
Why?
| | Multiple Sclerosis | 6 | 2013 | 384 | 0.860 |
Why?
| | Diffusion Tensor Imaging | 7 | 2023 | 73 | 0.820 |
Why?
| | Delusions | 4 | 2016 | 12 | 0.800 |
Why?
| | Cerebral Cortex | 6 | 2011 | 415 | 0.800 |
Why?
| | Neurobiology | 1 | 2021 | 18 | 0.790 |
Why?
| | Cocaine | 2 | 2022 | 158 | 0.770 |
Why?
| | Nervous System Diseases | 6 | 2017 | 261 | 0.750 |
Why?
| | Olfaction Disorders | 1 | 2021 | 47 | 0.750 |
Why?
| | Verbal Learning | 4 | 2019 | 73 | 0.730 |
Why?
| | Morals | 1 | 2020 | 67 | 0.730 |
Why?
| | Cerebral Palsy | 1 | 2021 | 80 | 0.710 |
Why?
| | Executive Function | 3 | 2019 | 390 | 0.700 |
Why?
| | Substance-Related Disorders | 7 | 2022 | 967 | 0.690 |
Why?
| | Diagnosis, Differential | 6 | 2021 | 1379 | 0.680 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2023 | 90 | 0.660 |
Why?
| | Infarction, Anterior Cerebral Artery | 1 | 2017 | 2 | 0.620 |
Why?
| | Social Behavior | 2 | 2020 | 275 | 0.610 |
Why?
| | Neurotoxicity Syndromes | 1 | 2017 | 15 | 0.600 |
Why?
| | Prosopagnosia | 1 | 2016 | 2 | 0.560 |
Why?
| | Capgras Syndrome | 1 | 2016 | 3 | 0.560 |
Why?
| | Low Back Pain | 1 | 2017 | 100 | 0.540 |
Why?
| | Brain Neoplasms | 4 | 2016 | 1019 | 0.520 |
Why?
| | Male | 78 | 2020 | 57479 | 0.520 |
Why?
| | Astrocytoma | 1 | 2016 | 112 | 0.510 |
Why?
| | Middle Aged | 48 | 2019 | 27514 | 0.480 |
Why?
| | Nerve Net | 1 | 2016 | 232 | 0.460 |
Why?
| | Inhalant Abuse | 1 | 2013 | 4 | 0.460 |
Why?
| | Occupational Exposure | 2 | 2015 | 275 | 0.460 |
Why?
| | Occupational Diseases | 1 | 2015 | 136 | 0.450 |
Why?
| | Myelinolysis, Central Pontine | 3 | 2011 | 5 | 0.450 |
Why?
| | Solvents | 3 | 2013 | 118 | 0.450 |
Why?
| | Hypertension | 2 | 2021 | 1199 | 0.430 |
Why?
| | Visual Fields | 1 | 2011 | 78 | 0.400 |
Why?
| | Female | 68 | 2023 | 61268 | 0.400 |
Why?
| | Brain Infarction | 1 | 2011 | 23 | 0.400 |
Why?
| | Presenilin-1 | 2 | 2009 | 29 | 0.390 |
Why?
| | Vision Disorders | 2 | 2011 | 135 | 0.380 |
Why?
| | History, 20th Century | 4 | 2019 | 281 | 0.380 |
Why?
| | Brain Damage, Chronic | 4 | 1999 | 24 | 0.380 |
Why?
| | Neurodegenerative Diseases | 1 | 2011 | 99 | 0.360 |
Why?
| | Memory, Short-Term | 3 | 2019 | 232 | 0.360 |
Why?
| | History, 19th Century | 3 | 2019 | 61 | 0.350 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2015 | 505 | 0.330 |
Why?
| | Neuroanatomy | 1 | 2008 | 12 | 0.330 |
Why?
| | Genetic Techniques | 1 | 2009 | 60 | 0.330 |
Why?
| | Aged | 33 | 2023 | 19599 | 0.320 |
Why?
| | Myokymia | 1 | 2007 | 3 | 0.320 |
Why?
| | Schizophrenia, Paranoid | 1 | 2007 | 10 | 0.320 |
Why?
| | Genetic Testing | 3 | 2014 | 388 | 0.310 |
Why?
| | Presenilin-2 | 1 | 2007 | 4 | 0.310 |
Why?
| | Adult | 43 | 2022 | 31327 | 0.310 |
Why?
| | Atrophy | 4 | 2013 | 164 | 0.310 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2007 | 50 | 0.300 |
Why?
| | Depression | 2 | 2013 | 1133 | 0.300 |
Why?
| | Aphasia, Primary Progressive | 1 | 2006 | 7 | 0.290 |
Why?
| | Multilingualism | 1 | 2006 | 28 | 0.290 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2007 | 128 | 0.290 |
Why?
| | Mental Recall | 3 | 2013 | 180 | 0.290 |
Why?
| | Huntington Disease | 1 | 2007 | 41 | 0.290 |
Why?
| | Behavior | 2 | 1998 | 94 | 0.280 |
Why?
| | Behavioral Sciences | 1 | 2005 | 9 | 0.280 |
Why?
| | Gangliosidoses, GM2 | 1 | 2005 | 1 | 0.270 |
Why?
| | Trinucleotide Repeat Expansion | 2 | 2016 | 26 | 0.270 |
Why?
| | Psychiatry | 1 | 2009 | 200 | 0.270 |
Why?
| | Fatal Outcome | 3 | 2016 | 286 | 0.260 |
Why?
| | Heterozygote | 2 | 2016 | 260 | 0.260 |
Why?
| | Cerebral Infarction | 4 | 2003 | 45 | 0.250 |
Why?
| | Autopsy | 2 | 2023 | 89 | 0.240 |
Why?
| | Lymphoma | 1 | 2005 | 179 | 0.240 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 18 | 0.230 |
Why?
| | History, 21st Century | 3 | 2010 | 170 | 0.230 |
Why?
| | Speech Disorders | 2 | 2019 | 35 | 0.230 |
Why?
| | Aging | 5 | 2019 | 1675 | 0.230 |
Why?
| | Central Nervous System Neoplasms | 1 | 2005 | 128 | 0.230 |
Why?
| | Stress Disorders, Post-Traumatic | 4 | 2021 | 760 | 0.230 |
Why?
| | Geriatric Psychiatry | 1 | 2002 | 12 | 0.210 |
Why?
| | Frontotemporal Dementia | 1 | 2022 | 31 | 0.210 |
Why?
| | Functional Laterality | 5 | 2019 | 208 | 0.210 |
Why?
| | Central Nervous System | 1 | 2004 | 243 | 0.200 |
Why?
| | Gray Matter | 1 | 2022 | 66 | 0.200 |
Why?
| | Choline | 3 | 2013 | 109 | 0.200 |
Why?
| | Stroke | 3 | 2007 | 1046 | 0.200 |
Why?
| | Dementia, Multi-Infarct | 2 | 1999 | 3 | 0.200 |
Why?
| | Genetic Variation | 2 | 2021 | 912 | 0.200 |
Why?
| | Coffee | 1 | 2021 | 14 | 0.200 |
Why?
| | Health Services for the Aged | 1 | 2002 | 71 | 0.200 |
Why?
| | Wechsler Scales | 5 | 1999 | 57 | 0.200 |
Why?
| | Reference Values | 8 | 2013 | 770 | 0.190 |
Why?
| | Palliative Care | 2 | 2017 | 631 | 0.190 |
Why?
| | Intelligence | 4 | 2010 | 136 | 0.190 |
Why?
| | Prognosis | 2 | 2022 | 3425 | 0.190 |
Why?
| | Veterans | 4 | 2021 | 1215 | 0.190 |
Why?
| | Animals | 11 | 2023 | 33152 | 0.190 |
Why?
| | Smell | 1 | 2021 | 118 | 0.180 |
Why?
| | Corpus Callosum | 2 | 2015 | 57 | 0.180 |
Why?
| | Neurosciences | 1 | 2020 | 22 | 0.180 |
Why?
| | Fornix, Brain | 1 | 2019 | 6 | 0.180 |
Why?
| | Aged, 80 and over | 11 | 2019 | 6541 | 0.180 |
Why?
| | Athletes | 1 | 2023 | 342 | 0.180 |
Why?
| | Neuroimaging | 4 | 2023 | 256 | 0.180 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 1999 | 14 | 0.170 |
Why?
| | Cooperative Behavior | 1 | 2002 | 401 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 4523 | 0.170 |
Why?
| | Memory, Episodic | 1 | 2019 | 42 | 0.170 |
Why?
| | Cerebral Arterial Diseases | 1 | 1999 | 43 | 0.170 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 1999 | 39 | 0.170 |
Why?
| | Reading | 4 | 2010 | 156 | 0.160 |
Why?
| | Violence | 1 | 2001 | 218 | 0.160 |
Why?
| | Radiation Injuries | 1 | 1999 | 131 | 0.160 |
Why?
| | Dementia, Vascular | 3 | 2008 | 20 | 0.160 |
Why?
| | Neurocognitive Disorders | 1 | 1998 | 25 | 0.160 |
Why?
| | Love | 1 | 1998 | 12 | 0.160 |
Why?
| | Autoantibodies | 3 | 2011 | 1334 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2491 | 0.150 |
Why?
| | Aneurysm, Ruptured | 1 | 1998 | 38 | 0.150 |
Why?
| | Subarachnoid Hemorrhage | 1 | 1998 | 64 | 0.150 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 214 | 0.150 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2008 | 105 | 0.140 |
Why?
| | Intracranial Aneurysm | 1 | 1998 | 99 | 0.140 |
Why?
| | Attention | 6 | 2011 | 407 | 0.140 |
Why?
| | Hippocampus | 5 | 2011 | 735 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 1999 | 246 | 0.140 |
Why?
| | Antiphospholipid Syndrome | 1 | 2016 | 29 | 0.140 |
Why?
| | Stress, Psychological | 1 | 2004 | 967 | 0.140 |
Why?
| | Parkinsonian Disorders | 1 | 2016 | 29 | 0.140 |
Why?
| | Movement Disorders | 1 | 2016 | 45 | 0.140 |
Why?
| | Neurologic Examination | 5 | 2009 | 126 | 0.140 |
Why?
| | Lewy Bodies | 1 | 1995 | 4 | 0.140 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 216 | 0.130 |
Why?
| | Air Pollutants | 1 | 1999 | 304 | 0.130 |
Why?
| | Age of Onset | 4 | 2016 | 465 | 0.130 |
Why?
| | Ethics, Medical | 1 | 1996 | 73 | 0.130 |
Why?
| | Psychomotor Performance | 4 | 2013 | 289 | 0.130 |
Why?
| | Educational Status | 1 | 1997 | 437 | 0.120 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2010 | 191 | 0.120 |
Why?
| | Aspartic Acid | 3 | 2011 | 85 | 0.120 |
Why?
| | Nerve Degeneration | 1 | 1994 | 43 | 0.120 |
Why?
| | Military Personnel | 1 | 2021 | 527 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2017 | 481 | 0.120 |
Why?
| | Cholinergic Fibers | 2 | 1999 | 19 | 0.120 |
Why?
| | United States | 6 | 2022 | 12496 | 0.120 |
Why?
| | Dyslexia | 2 | 2007 | 84 | 0.120 |
Why?
| | Cerebellum | 1 | 2015 | 203 | 0.110 |
Why?
| | Trauma Severity Indices | 2 | 2011 | 122 | 0.110 |
Why?
| | Creatine | 2 | 2011 | 55 | 0.110 |
Why?
| | Memory | 5 | 2011 | 230 | 0.110 |
Why?
| | Visual Field Tests | 1 | 2011 | 14 | 0.100 |
Why?
| | Hemianopsia | 1 | 2011 | 10 | 0.100 |
Why?
| | Parkinson Disease | 2 | 1995 | 334 | 0.100 |
Why?
| | Risk Factors | 7 | 2019 | 8958 | 0.100 |
Why?
| | Myelin Sheath | 2 | 2011 | 148 | 0.100 |
Why?
| | Chronic Disease | 3 | 2015 | 1631 | 0.100 |
Why?
| | Creatinine | 1 | 2013 | 491 | 0.100 |
Why?
| | Brain Chemistry | 2 | 2009 | 118 | 0.100 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2009 | 499 | 0.100 |
Why?
| | Facial Expression | 2 | 2022 | 62 | 0.090 |
Why?
| | Regression Analysis | 1 | 2013 | 984 | 0.090 |
Why?
| | Residence Characteristics | 1 | 2013 | 297 | 0.090 |
Why?
| | Brain Ischemia | 2 | 2005 | 309 | 0.090 |
Why?
| | History, 15th Century | 1 | 2010 | 12 | 0.090 |
Why?
| | History, 17th Century | 1 | 2010 | 18 | 0.090 |
Why?
| | History, 16th Century | 1 | 2010 | 16 | 0.090 |
Why?
| | History, 18th Century | 1 | 2010 | 23 | 0.090 |
Why?
| | History, Ancient | 1 | 2010 | 58 | 0.090 |
Why?
| | History, Medieval | 1 | 2010 | 43 | 0.090 |
Why?
| | Antipsychotic Agents | 2 | 2007 | 192 | 0.090 |
Why?
| | Demyelinating Diseases | 2 | 1995 | 79 | 0.090 |
Why?
| | Education | 2 | 2007 | 104 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2017 | 12932 | 0.090 |
Why?
| | Combat Disorders | 1 | 2009 | 34 | 0.090 |
Why?
| | Nerve Tissue | 1 | 2008 | 8 | 0.080 |
Why?
| | Apolipoprotein E4 | 1 | 2009 | 37 | 0.080 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2009 | 55 | 0.080 |
Why?
| | Mental Health Services | 2 | 2010 | 331 | 0.080 |
Why?
| | Genetic Counseling | 1 | 2009 | 66 | 0.080 |
Why?
| | Amnesia | 2 | 1991 | 46 | 0.080 |
Why?
| | Models, Anatomic | 1 | 2008 | 94 | 0.080 |
Why?
| | Antibodies | 1 | 2010 | 381 | 0.080 |
Why?
| | Isaacs Syndrome | 1 | 2007 | 5 | 0.080 |
Why?
| | Forensic Psychiatry | 1 | 2008 | 26 | 0.080 |
Why?
| | Neurofibrillary Tangles | 1 | 2007 | 16 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2007 | 20 | 0.080 |
Why?
| | Verbal Behavior | 4 | 2013 | 48 | 0.080 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2007 | 33 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1787 | 0.080 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 19 | 0.080 |
Why?
| | Academic Medical Centers | 1 | 2010 | 422 | 0.080 |
Why?
| | Peripheral Nerves | 1 | 2007 | 65 | 0.080 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 72 | 0.080 |
Why?
| | Axons | 1 | 2009 | 183 | 0.080 |
Why?
| | Vertebral Artery | 1 | 2007 | 27 | 0.070 |
Why?
| | Social Behavior Disorders | 1 | 1987 | 15 | 0.070 |
Why?
| | Wasting Disease, Chronic | 1 | 2007 | 19 | 0.070 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 33 | 0.070 |
Why?
| | Mental Competency | 1 | 2007 | 27 | 0.070 |
Why?
| | Syndrome | 1 | 2007 | 343 | 0.070 |
Why?
| | Prednisone | 1 | 2007 | 235 | 0.070 |
Why?
| | Alcoholism | 1 | 1993 | 714 | 0.070 |
Why?
| | Introns | 1 | 2007 | 233 | 0.070 |
Why?
| | Affective Symptoms | 1 | 1987 | 50 | 0.070 |
Why?
| | Hepatolenticular Degeneration | 1 | 2006 | 18 | 0.070 |
Why?
| | Association Learning | 1 | 2007 | 59 | 0.070 |
Why?
| | Point Mutation | 1 | 2007 | 227 | 0.070 |
Why?
| | Parietal Lobe | 1 | 2006 | 42 | 0.070 |
Why?
| | Intelligence Tests | 4 | 2010 | 63 | 0.070 |
Why?
| | Motor Skills | 1 | 2007 | 84 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2007 | 142 | 0.070 |
Why?
| | Depressive Disorder, Major | 1 | 2009 | 302 | 0.070 |
Why?
| | Electromyography | 1 | 2007 | 326 | 0.070 |
Why?
| | Methanol | 2 | 1997 | 35 | 0.070 |
Why?
| | Blood Platelets | 3 | 1994 | 344 | 0.070 |
Why?
| | Prion Diseases | 1 | 2005 | 11 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2010 | 644 | 0.070 |
Why?
| | Bipolar Disorder | 1 | 2007 | 209 | 0.070 |
Why?
| | Craniocerebral Trauma | 1 | 1987 | 146 | 0.060 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 192 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2006 | 3676 | 0.060 |
Why?
| | Health Surveys | 1 | 2007 | 453 | 0.060 |
Why?
| | Prions | 1 | 2005 | 36 | 0.060 |
Why?
| | MEDLINE | 1 | 2005 | 24 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2009 | 554 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2016 | 3156 | 0.060 |
Why?
| | Optic Nerve | 1 | 2005 | 65 | 0.060 |
Why?
| | Electron Transport Complex IV | 3 | 1994 | 53 | 0.060 |
Why?
| | Pilot Projects | 2 | 2019 | 1405 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 641 | 0.060 |
Why?
| | Lymphoma, B-Cell | 1 | 2005 | 85 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 466 | 0.060 |
Why?
| | Cytokines | 1 | 2011 | 1880 | 0.060 |
Why?
| | Adolescent | 14 | 2010 | 18364 | 0.060 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 94 | 0.060 |
Why?
| | Statistics, Nonparametric | 3 | 2009 | 400 | 0.060 |
Why?
| | Intellectual Disability | 1 | 2005 | 136 | 0.060 |
Why?
| | Child | 8 | 2010 | 19033 | 0.060 |
Why?
| | Immunotherapy | 1 | 2007 | 493 | 0.060 |
Why?
| | Gliosis | 1 | 2023 | 35 | 0.060 |
Why?
| | Neurites | 1 | 2023 | 45 | 0.060 |
Why?
| | Astrocytes | 1 | 2005 | 176 | 0.060 |
Why?
| | Alleles | 2 | 2016 | 829 | 0.060 |
Why?
| | Colorado | 4 | 2017 | 4178 | 0.060 |
Why?
| | Neuromyelitis Optica | 1 | 1984 | 112 | 0.060 |
Why?
| | Microglia | 1 | 2005 | 220 | 0.060 |
Why?
| | Evoked Potentials, Auditory | 3 | 2000 | 200 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2009 | 2262 | 0.050 |
Why?
| | Podophyllin | 1 | 1982 | 2 | 0.050 |
Why?
| | Spinal Cord | 1 | 2005 | 367 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 667 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2004 | 652 | 0.050 |
Why?
| | Brain Mapping | 2 | 2010 | 530 | 0.050 |
Why?
| | Social Conditions | 1 | 2001 | 13 | 0.050 |
Why?
| | Biopsy | 1 | 2005 | 1078 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2545 | 0.050 |
Why?
| | Mental Status Schedule | 2 | 1999 | 38 | 0.050 |
Why?
| | Mutation | 2 | 2009 | 3435 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2007 | 778 | 0.050 |
Why?
| | Head Injuries, Penetrating | 1 | 2000 | 8 | 0.050 |
Why?
| | Synaptic Vesicles | 1 | 2000 | 38 | 0.050 |
Why?
| | Ophthalmoplegia | 1 | 1999 | 9 | 0.050 |
Why?
| | Emotions | 2 | 2022 | 494 | 0.050 |
Why?
| | Facial Paralysis | 1 | 1999 | 17 | 0.050 |
Why?
| | Brain Injury, Chronic | 1 | 2000 | 24 | 0.040 |
Why?
| | Pons | 1 | 1999 | 31 | 0.040 |
Why?
| | Neocortex | 1 | 2000 | 25 | 0.040 |
Why?
| | Apraxias | 1 | 2019 | 9 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 2000 | 55 | 0.040 |
Why?
| | Electron Transport | 3 | 1994 | 101 | 0.040 |
Why?
| | Lung Diseases, Obstructive | 1 | 1999 | 44 | 0.040 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 1999 | 25 | 0.040 |
Why?
| | Aggression | 1 | 2001 | 184 | 0.040 |
Why?
| | Psychometrics | 2 | 1996 | 625 | 0.040 |
Why?
| | Sensory Thresholds | 1 | 1999 | 30 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2000 | 215 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 5 | 2007 | 2433 | 0.040 |
Why?
| | Self Report | 1 | 2022 | 698 | 0.040 |
Why?
| | Epidermal Growth Factor | 1 | 1999 | 172 | 0.040 |
Why?
| | Caudate Nucleus | 2 | 1997 | 16 | 0.040 |
Why?
| | Diseases in Twins | 1 | 1999 | 181 | 0.040 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 239 | 0.040 |
Why?
| | Basilar Artery | 1 | 1998 | 7 | 0.040 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1515 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2007 | 9319 | 0.040 |
Why?
| | Obesity | 1 | 2011 | 2715 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 1999 | 508 | 0.040 |
Why?
| | Follow-Up Studies | 4 | 1998 | 4575 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2017 | 78 | 0.040 |
Why?
| | Behavioral Symptoms | 1 | 1997 | 43 | 0.040 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2016 | 22 | 0.040 |
Why?
| | Comorbidity | 1 | 2021 | 1516 | 0.040 |
Why?
| | Biological Evolution | 1 | 2001 | 439 | 0.040 |
Why?
| | Linear Models | 2 | 2009 | 817 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2017 | 189 | 0.040 |
Why?
| | Craniopharyngioma | 1 | 1997 | 70 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2000 | 548 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 129 | 0.030 |
Why?
| | Tacrine | 1 | 1995 | 1 | 0.030 |
Why?
| | Pituitary Neoplasms | 1 | 1997 | 165 | 0.030 |
Why?
| | Arcuate Nucleus of Hypothalamus | 1 | 1995 | 14 | 0.030 |
Why?
| | Program Development | 1 | 2017 | 355 | 0.030 |
Why?
| | Mitochondria | 4 | 1994 | 785 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 262 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2008 | 2856 | 0.030 |
Why?
| | Cohort Studies | 2 | 2016 | 5078 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 1995 | 90 | 0.030 |
Why?
| | Encephalitis, Viral | 1 | 1995 | 42 | 0.030 |
Why?
| | Acetylcholine | 2 | 2010 | 208 | 0.030 |
Why?
| | Nerve Fibers | 1 | 1995 | 89 | 0.030 |
Why?
| | Family Health | 1 | 1996 | 201 | 0.030 |
Why?
| | Raphe Nuclei | 1 | 1995 | 118 | 0.030 |
Why?
| | Nursing Homes | 1 | 1996 | 130 | 0.030 |
Why?
| | Skin | 1 | 1999 | 657 | 0.030 |
Why?
| | Estrogens | 1 | 1997 | 329 | 0.030 |
Why?
| | Herpesviridae Infections | 1 | 1995 | 140 | 0.030 |
Why?
| | Central Nervous System Agents | 1 | 1993 | 6 | 0.030 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 1993 | 33 | 0.030 |
Why?
| | Language | 2 | 2005 | 271 | 0.030 |
Why?
| | Patient Care Team | 1 | 2017 | 521 | 0.030 |
Why?
| | Hypoxia | 1 | 1999 | 957 | 0.030 |
Why?
| | New York City | 1 | 2013 | 75 | 0.030 |
Why?
| | Counseling | 1 | 1995 | 346 | 0.030 |
Why?
| | Lymphomatoid Granulomatosis | 1 | 1992 | 4 | 0.030 |
Why?
| | Lymphoma, T-Cell | 1 | 1992 | 22 | 0.030 |
Why?
| | Social Support | 1 | 1995 | 527 | 0.030 |
Why?
| | Quality of Life | 1 | 2022 | 2355 | 0.030 |
Why?
| | Forensic Medicine | 1 | 2011 | 16 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1990 | 2 | 0.020 |
Why?
| | Brain Stem | 2 | 1988 | 104 | 0.020 |
Why?
| | Expert Testimony | 1 | 2011 | 56 | 0.020 |
Why?
| | Visual Perception | 1 | 2011 | 141 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 524 | 0.020 |
Why?
| | Disability Evaluation | 2 | 2009 | 278 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 962 | 0.020 |
Why?
| | Age Factors | 3 | 1986 | 2990 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 10731 | 0.020 |
Why?
| | Time Factors | 2 | 2013 | 6368 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2009 | 57 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2011 | 223 | 0.020 |
Why?
| | AIDS Dementia Complex | 1 | 2009 | 51 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2009 | 115 | 0.020 |
Why?
| | Prospective Studies | 2 | 2011 | 6443 | 0.020 |
Why?
| | Neuropsychology | 1 | 2009 | 31 | 0.020 |
Why?
| | Inclusion Bodies | 1 | 1988 | 25 | 0.020 |
Why?
| | Ethanol | 1 | 1993 | 574 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2009 | 146 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 2937 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2009 | 324 | 0.020 |
Why?
| | Cysticercosis | 1 | 1987 | 4 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2007 | 25 | 0.020 |
Why?
| | Electroencephalography | 2 | 2000 | 387 | 0.020 |
Why?
| | Cerebral Hemorrhage | 2 | 1987 | 100 | 0.020 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2009 | 219 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 470 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 298 | 0.020 |
Why?
| | Research | 1 | 2011 | 406 | 0.020 |
Why?
| | Aphasia | 1 | 1987 | 23 | 0.020 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2007 | 6 | 0.020 |
Why?
| | Disease Reservoirs | 1 | 2007 | 20 | 0.020 |
Why?
| | Coma | 1 | 1987 | 32 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2007 | 116 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2007 | 45 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1857 | 0.020 |
Why?
| | Prolactin | 1 | 2007 | 96 | 0.020 |
Why?
| | Thyrotropin | 1 | 2007 | 104 | 0.020 |
Why?
| | Xylenes | 1 | 1986 | 8 | 0.020 |
Why?
| | Organ Size | 1 | 2007 | 460 | 0.020 |
Why?
| | Prevalence | 1 | 2013 | 2321 | 0.020 |
Why?
| | Accidents, Traffic | 1 | 2007 | 176 | 0.020 |
Why?
| | Biomarkers | 2 | 2011 | 3568 | 0.020 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 152 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 993 | 0.020 |
Why?
| | Postoperative Complications | 1 | 1997 | 2230 | 0.020 |
Why?
| | Liver Failure | 1 | 2006 | 85 | 0.020 |
Why?
| | Space Perception | 1 | 1986 | 65 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1288 | 0.020 |
Why?
| | Mental Processes | 1 | 2005 | 35 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2659 | 0.020 |
Why?
| | Sodium | 1 | 2006 | 200 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2007 | 210 | 0.020 |
Why?
| | Athletic Injuries | 1 | 1991 | 476 | 0.020 |
Why?
| | Psychological Tests | 1 | 1985 | 127 | 0.020 |
Why?
| | Recurrence | 1 | 2007 | 971 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2005 | 379 | 0.010 |
Why?
| | Pedigree | 1 | 2005 | 485 | 0.010 |
Why?
| | Dyslexia, Acquired | 1 | 2003 | 2 | 0.010 |
Why?
| | Agraphia | 1 | 2003 | 3 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 690 | 0.010 |
Why?
| | Auditory Perceptual Disorders | 1 | 2003 | 11 | 0.010 |
Why?
| | Anticoagulants | 1 | 2007 | 555 | 0.010 |
Why?
| | Condylomata Acuminata | 1 | 1982 | 7 | 0.010 |
Why?
| | Psychoses, Substance-Induced | 1 | 1982 | 14 | 0.010 |
Why?
| | Hallucinations | 1 | 1982 | 29 | 0.010 |
Why?
| | Autonomic Nervous System Diseases | 1 | 1982 | 28 | 0.010 |
Why?
| | Neural Conduction | 1 | 1982 | 81 | 0.010 |
Why?
| | Comprehension | 1 | 2003 | 162 | 0.010 |
Why?
| | Entorhinal Cortex | 1 | 2001 | 10 | 0.010 |
Why?
| | Genital Neoplasms, Female | 1 | 1982 | 72 | 0.010 |
Why?
| | rab3A GTP-Binding Protein | 1 | 2000 | 1 | 0.010 |
Why?
| | Synapsins | 1 | 2000 | 13 | 0.010 |
Why?
| | Qa-SNARE Proteins | 1 | 2000 | 14 | 0.010 |
Why?
| | R-SNARE Proteins | 1 | 2000 | 19 | 0.010 |
Why?
| | Synaptosomal-Associated Protein 25 | 1 | 2000 | 26 | 0.010 |
Why?
| | Synaptotagmins | 1 | 2000 | 21 | 0.010 |
Why?
| | Lewy Body Disease | 1 | 2000 | 15 | 0.010 |
Why?
| | Facial Nerve | 1 | 1999 | 32 | 0.010 |
Why?
| | Immunoblotting | 1 | 2000 | 304 | 0.010 |
Why?
| | Macrophages | 1 | 2006 | 1311 | 0.010 |
Why?
| | Volition | 1 | 1999 | 33 | 0.010 |
Why?
| | Muscle Weakness | 1 | 1999 | 82 | 0.010 |
Why?
| | Receptors, Cholinergic | 1 | 1999 | 46 | 0.010 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2000 | 140 | 0.010 |
Why?
| | Reaction Time | 1 | 2000 | 390 | 0.010 |
Why?
| | Kinetics | 2 | 1993 | 1623 | 0.010 |
Why?
| | Oxygen Inhalation Therapy | 1 | 1999 | 124 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2000 | 334 | 0.010 |
Why?
| | Disease Progression | 1 | 2005 | 2477 | 0.010 |
Why?
| | Putamen | 1 | 1997 | 14 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 443 | 0.010 |
Why?
| | Gadolinium | 1 | 1997 | 78 | 0.010 |
Why?
| | Achievement | 1 | 1997 | 57 | 0.010 |
Why?
| | Neurons | 1 | 2005 | 1340 | 0.010 |
Why?
| | Hypothalamus | 1 | 1997 | 155 | 0.010 |
Why?
| | Necrosis | 1 | 1997 | 230 | 0.010 |
Why?
| | Phosphorylation | 1 | 2001 | 1622 | 0.010 |
Why?
| | Image Enhancement | 1 | 1997 | 181 | 0.010 |
Why?
| | Contrast Media | 1 | 1997 | 373 | 0.010 |
Why?
| | Survivors | 1 | 1997 | 411 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2000 | 1048 | 0.010 |
Why?
| | Thiothixene | 1 | 1993 | 1 | 0.010 |
Why?
| | Chlorpromazine | 1 | 1993 | 5 | 0.010 |
Why?
| | Clozapine | 1 | 1993 | 21 | 0.010 |
Why?
| | Electron Transport Complex III | 1 | 1993 | 12 | 0.010 |
Why?
| | Haloperidol | 1 | 1993 | 36 | 0.010 |
Why?
| | Acute Disease | 1 | 1995 | 933 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 24 | 0.010 |
Why?
| | Brain Edema | 1 | 1991 | 61 | 0.010 |
Why?
| | Cytochrome-c Oxidase Deficiency | 1 | 1990 | 3 | 0.010 |
Why?
| | Capsules | 1 | 1990 | 35 | 0.010 |
Why?
| | Biological Availability | 1 | 1990 | 126 | 0.010 |
Why?
| | Child, Preschool | 2 | 1997 | 9448 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1993 | 1937 | 0.010 |
Why?
| | Aphasia, Broca | 1 | 1987 | 4 | 0.000 |
Why?
| | Hematoma, Epidural, Cranial | 1 | 1987 | 5 | 0.000 |
Why?
| | Language Tests | 1 | 1987 | 31 | 0.000 |
Why?
| | Mexico | 1 | 1987 | 164 | 0.000 |
Why?
| | Cerebellar Diseases | 1 | 1986 | 22 | 0.000 |
Why?
| | Cranial Nerve Diseases | 1 | 1986 | 42 | 0.000 |
Why?
| | Double-Blind Method | 1 | 1990 | 1683 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1990 | 964 | 0.000 |
Why?
| | Contraceptives, Oral | 1 | 1984 | 27 | 0.000 |
Why?
| | Rats | 1 | 1993 | 5339 | 0.000 |
Why?
| | Migraine Disorders | 1 | 1984 | 79 | 0.000 |
Why?
| | Heart Diseases | 1 | 1984 | 340 | 0.000 |
Why?
|
|
Filley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|